

Dieting Fate & Metabolism

Edited by
Edward R.
Garrett
and
Jean L. Hirtz

Methods
and
Techniques
Volume 5

DRUG FATE AND METABOLISM

Methods and Techniques

VOLUME 5

Edited by

EDWARD R. GARRETT

*The Beehive, College of Pharmacy
University of Florida
Gainesville, Florida*

JEAN L. HIRTZ

*Ciba-Geigy Biopharmaceutical
Research Center
Rueil-Malmaison, France*



Y076252



MARCEL DEKKER, INC. New York and Basel

Library of Congress Catalog Number: 76-28081

COPYRIGHT ©1985 by MARCEL DEKKER, INC.

ALL RIGHTS RESERVED

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

MARCEL DEKKER, INC.

270 Madison Avenue, New York, New York 10016

ISBN: 0-8247-7423-X

Current printing (last digit):

10 9 8 7 6 5 4 3 2 1

PRINTED IN THE UNITED STATES OF AMERICA

¥406.71元

DRUG FATE AND METABOLISM

Preface

Historically, the major emphasis in drug development was on the isolation and synthesis of active principles and the evaluation of their safety and efficacy in animals and man. The fate of drugs in the body, which includes their absorption, distribution, metabolism, and elimination, was not emphasized. Systematic studies on the fate of drugs in the body have been conducted only within the last several decades.

Such studies were inhibited by the inadequacies of analytical techniques and methods to isolate, identify, and assay the drugs and their metabolites in the biological tissues and fluids of the organism. Drug metabolism studies were performed as long as a century ago on quinine (1869), salicylic acid (1877), and morphine (1883) with the simple techniques then available. However, such studies were infrequently done and in limited depth until B. B. Brodie elaborated a general method for the discriminatory extraction of drugs and metabolites from biological fluids during World War II in connection with the United States' antimalarial screening program. At about the same time, L. C. Craig developed counter-current distribution procedures for separation and identification purposes. By modern standards, methods of quantification then available, which included colorimetry, fluorometry, and ultraviolet absorption spectroscopy, were insensitive and in the microgram per milliliter range.

Pharmacokinetics, the study of the time course of a drug's absorption, distribution, metabolism, and elimination, is another aspect in the fate of drugs and was of even later vintage. Its maturation also depended on the development of sensitive and reliable assays in biological fluids. Probably the first publication in this field of adequate sophistication was on ethanol in 1922. The basic principles of pharmacokinetics were elaborated by Torsten

Teorell of Uppsala in 1937, and the first book on the subject was published by F. H. Dost of Berlin, later of Giessen, in 1953. However, this field did not truly flower until the 1960s, and its initial blossoming was observed at the first international conference on the subject in 1962 held under the initiative of Ekkehard Krueger-Thiemer at Borstel Forschungsinstitut in Germany.

The burgeoning of these studies on drug fate in the organism was fertilized by the development of radiometric techniques when radiolabeled drugs became available. Gas-liquid chromatography, now the most widely used method, provided a simple and inexpensive technique to separate and quantify drugs and their metabolites. Sensitive detectors were developed to provide picogram monitoring of nonlabeled materials. Other analytical and separative methods of high sensitivity and precision became commonplace in the laboratory. Instrumentation became available and less expensive for detection (NMR, spectrofluorimetry, infrared, gas and mass spectrometry, immunoassay) and for separation (thin-layer and high pressure liquid chromatography, etc.).

Today, it can be stated that the sensitivity of analytical detection no longer limits investigation into the fate of drugs. Separation and purification still is a rate-determining factor in assay development and demands a multidisciplinary expert in biological, physical, organic, and analytical chemistry.

Similarly, the theoretical bases of pharmacokinetics and the technology of its applications have been expanded and refined within the last two decades. The generalized use of computers has permitted quantification of the models used to describe the totality of processes contributing to the time course of the drug in the body and to relate this time course to that of observed pharmacodynamics and pharmacological and toxicological action. The foundations of a modern pharmacology have been laid down, upon which structure personalized dosage regimens can be predicted for individualized optimum treatment with minimum toxicities; it is upon these premises that action and toxicities in one species can be predicted from studies performed on another.

The insights gained into the mechanisms of drug action provide clues to molecular modification that can best embody the active principle of action. Metabolic engineering can be construed as that practice which modifies the design of the molecule to take advantage of extant metabolic pathways to prolong or shorten the time of drug presence in the body. The clinical awareness that the rate and extent of drug release from a dosage form can perturb the availability

and delivery of therapeutic agents has led to the necessity of establishing standards for bioequivalences of formulations. Pharmacokinetics now serves as a basis for these biopharmaceutical necessities.

It is therefore not surprising that the study of drug absorption, distribution, metabolism, and excretion constitutes a large part of the modern research for new and more efficient therapeutic agents. Governmental regulatory agencies in various countries now require precise data on the fate of new drugs and their formulations in animals and man and are increasingly insistent on stricter compliance.

Although there are several books dealing separately with drug metabolism, drug disposition, pharmacokinetics, and the like, a proper compendium has been lacking which encompasses the various fields and provides a delineation and appropriate critique of the useful methods and techniques that can be applied in them.

One of the editors (JLH) published (1968) a book on the analytical techniques (*Les Méthodes Analytiques dans les Recherches sur le Métabolisme des Médicaments*, Masson, Paris) which was later translated by editor ERG into English (*Analytical Metabolic Chemistry of Drugs*, Marcel Dekker, New York, 1971). The reception of this book was gratifying and prompted us to bring out the present more comprehensive and modernized series of volumes which includes other methods and techniques in the study of drug fate, not only analytical procedures. Since this ambitious goal exceeded the expertise of only one or a few authors, a multiauthor series was projected. Experts were chosen who were highly respected in their fields. We reserved the right, and exercised it, to edit and revise to maintain a reasonable level of homogeneity in conformance with the objectives of the series. We hope we have succeeded.

The intent of these volumes is to review all the techniques, physical, chemical, biological, medical, and mathematical, which can be applied to the study of drug fate in the organism. It is addressed primarily to the research scientist and is devoted to *methods*, with only the minimal theory given for perspective, appreciation, and proper evaluation of results. The intent was not to compete with the many fine theoretical texts available, but to provide a broad spectrum of information that can be readily utilized by the research worker.

The practical use of these methods is explored fully. The limitations are explained. Necessary precautions and sources of error are delineated. Examples are given of applications in the study of fate of drugs. When possible, each chapter includes tables that

condense the appropriate literature on the particular topic. Each chapter has a selected, adequate, but not exhaustive, bibliography.

It was deemed proper to include chapters on methods that would not be modern methods of choice but are of historical importance in evaluating the significance and limitations of the earlier studies in these fields. Whenever possible, a critique is provided, the future development is predicted, and the utility of a considered technique is evaluated.

In order not to delay the publications of up-to-date reviews, the chapters were published in the approximate order that they were received from the authors. Although this may at times put subjects adjacent that are from divergent subdisciplines in the field of drug fate and metabolism, the benefits to the readership of prompt publication would far outweigh the need for subclassification of the various topics.

It is our sincere hope that these endeavors of our dedicated authors will serve the desired purpose.

Edward R. Garrett
Jean L. Hirtz

Contributors

STUART L. BEAL

Laboratory Medicine, University of California at San Francisco,
San Francisco, California

LUIGI BOTTA

Ciba-Geigy Limited, Pharma Research and Development, Basel,
Switzerland

ROKUS A. de ZEEUW

Department of Toxicology, State University, Groningen, The
Netherlands

BEN F. H. DRENTH

Department of Toxicology, State University, Groningen, The
Netherlands

EDWARD R. GARRETT

J. Hillis Miller Health Center, College of Pharmacy, University
of Florida, Gainesville, Florida

HANS-ULRICH GERBER

Ciba-Geigy Limited, Pharma Research and Development, Basel,
Switzerland

ALAIN GOUYETTE

Unité de Biochimie-Enzymologie, Institut Gustave-Roussy,
Villejuif, France

GRAHAM F. READ

Tenovus Institute for Cancer Research, University of Wales,
College of Medicine, Cardiff, Wales

DIANA RIAD-FAHMY

Tenovus Institute for Cancer Research, University of Wales,
College of Medicine, Cardiff, Wales

KARL SCHMID

Ciba-Geigy Limited, Pharma Research and Development, Basel,
Switzerland

LEWIS B. SHEINER

Laboratory Medicine, University of California at San Francisco,
San Francisco, California

Contents of Other Volumes

Volume 1

AUTORADIOGRAPHY

William J. Waddell and Carolyn Marlowe

AUTORADIOGRAPHY IN CYTOPHARMACOLOGY

Lloyd J. Roth, Ihsan M. Diab, Mitsuotoshi Watanabe, and
Robert J. Dinerstein

ELECTROPHORESIS

Walter D. Conway

ION-PAIR EXTRACTION AND CHROMATOGRAPHY

Göran Schill, Rolf Modin, Karl Olof Borg, and Bengt-Arne
Persson

PROTEIN BINDING

Colin F. Chignell

ATOMIC ABSORPTION SPECTROSCOPY

Manfred Harth, D. S. Milton Haines, and Donald C. Bondy

SPIN IMMUNOASSAY

Mark R. Montgomery, Jordan L. Holtzman, and Richard K. Leute

ANIMAL CARE AND USE

John W. Ward and John R. Elsea

Volume 2

VOLTAMMETRIC METHODS

J. Arthur F. de Silva and Marvin A. Brooks

GAS-LIQUID CHROMATOGRAPHY

W. J. A. VandenHeuvel and A. G. Zacchei

STEREOCHEMICAL METHODOLOGY

Bernard Testa and Peter Jenner

FLUORESCENCE SPECTROSCOPY

Stephen G. Schulman and Datta V. Naik

NONRADIOACTIVE IMMUNOASSAYS

Joseph Haimovich and Michael Sela

ANALYSIS OF GLUCURONIC ACID CONJUGATES

Jelka Tomasić

Volume 3

MASS FRAGMENTOGRAPHY

E. L. Ghisalberti

PAPER CHROMATOGRAPHY

Hans J. Nestler

SYNTHESIS OF ISOTOPICALLY LABELED COMPOUNDS

Holly E. Mertel

COLORIMETRY

M. Pesez and J. Bartos

RADIOACTIVATION ANALYSIS

D. Comar and B. Maziere

STUDY OF DRUG-PROTEIN INTERACTION WITH DIFFUSIVITY MEASUREMENTS

J. L. Chanal and R. Marignan

PHYSIOLOGIC AND METABOLIC VARIABLES IN BIOAVAILABILITY STUDIES

Stanley A. Kaplan and Margaret L. Jack

Volume 4

COMPUTER USE IN PHARMACOKINETICS

Luc P. Balant and Edward R. Garrett

PREANALYTICAL METHODOLOGY FOR DRUG ANALYSIS IN
BIOLOGICAL FLUIDS

Jimmie L. Valentine

ISOTOPE DERIVATIZATION ANALYSIS

J. Godbillon

ELECTRON CAPTURE GAS-LIQUID CHROMATOGRAPHY IN
DRUG ANALYSIS

J. Arthur F. de Silva and Carl V. Puglisi

ANIMAL SPECIES

Howard B. Huckler

QUANTITATIVE PHARMACO-EEG IN DETERMINING BIOAVAILA-
BILITY AND BIOEQUIVALENCY OF PSYCHOTROPIC DRUGS

Turan M. Itil and Victor E. Krynicki

Contents

Preface	iii
Contributors	xi
Contents of Other Volumes	xiii
Chapter 1 Pharmacokinetic Procedures and Strategies	1
Edward R. Garrett	
I. Introduction	4
II. Outline of Typical Pharmacokinetic Procedures	5
III. Strategies to Evaluate Pharmacokinetic Models	10
IV. Evaluation of Dose-Dependent or Dose- Independent Pharmacokinetics	11
V. Possible Assignments of Dose-Dependent Pharmacokinetics to Renal Processes	14
VI. Possible Assignment of Dose-Dependent Pharmacokinetics to Biliary Processes . . .	21
VII. Possible Assignments of Dose-Dependent Processes to Metabolic Processes	21
VIII. Possible Assignments of Dose-Dependent Processes to Distributive Processes	27
IX. Assessment of Presence of Multiple or Deep Compartments and Their Possible Clinical Significance	28
X. Assessment of the Properties of the Biophase Compartment for the Site of Drug Action	36

	XI. Assessment of the Bioavailabilities of Orally Administered Drug	37
	XII. The Fitting of Models in Pharmacokinetic Analysis.	39
	Appendix I: Summary of Calculation of Usual "Classical" Major Pharmacokinetic Parameters	40
	Appendix II: Summary of Usual Routine Data Manipulation and Plotting in Pharmacokinetic Studies	46
	References	49
Chapter 2	Radio- and Enzyme-Immunoassays.	51
	Diana Riad-Fahmy and Graham F. Read	
	I. Introduction.	52
	II. General Considerations	53
	III. Production of Antisera	56
	IV. Antigen Labels	66
	V. Choice of Biological Fluid for Assay	72
	VI. Classic Format of Immunoassays	74
	VII. Establishment of Immunoassays	84
	VIII. Assay Validation	86
	IX. Quality Control	93
	X. Conclusions	95
	References	95
Chapter 3	Measurement of Radioactivity in Biological Experiments	99
	Luigi Botta, Hans-Ulrich Gerber, and Karl Schmid	
	I. Introduction.	99
	II. Liquid Scintillation Counting	100
	III. LSC in Combination with Other Techniques	130
	References	133
Chapter 4	Methodology of Population Pharmacokinetics	135
	Stuart L. Beal and Lewis B. Sheiner	
	I. Introduction.	135
	II. The Standard Two-Stage Method	139

III.	The First Order Method	155
IV.	The Two-Stage ELS Method	168
Appendix I:	Confidence Intervals for Measures of Population Dispersion	173
Appendix II:	Two-Stage Extended Least- Squares Estimates for Model . .	175
Appendix III:	Model Used by Grasela and Sheiner (1984)	177
References	181
Chapter 5	High-Performance Liquid Chromatography . . .	185
	Ben F. H. Drenth and Rokus A. de Zeeuw	
	I. Basic Concepts	186
	II. Stationary and Mobile Phases	192
	III. The HPLC Apparatus and Its Use in Practice	198
	IV. Derivitization	205
	V. Sample Preparation	207
	VI. Applications of HPLC in the Area of Drug Fate and Metabolism	210
	VII. Conclusion.	225
	References	225
Chapter 6	Liquid Chromatography-Mass Spectrometry: Techniques and Applications	247
	Alain Gouyette	
	I. Introduction.	247
	II. LC-MS Techniques	248
	III. Applications	251
	IV. Discussion	267
	References	268
	Author Index (Volumes 1-5)	273
	Subject Index (Volumes 1-5)	297

Pharmacokinetic Procedures and Strategies

Edward R. Garrett

J. Hillis Miller Health Center
College of Pharmacy
University of Florida
Gainesville, Florida

I. Introduction	4
II. Outline of Typical Pharmacokinetic Procedures	5
A. Assay considerations	5
B. Choosing individual animals or humans	6
C. Protocols for sampling	7
D. Some possible dose designs	8
III. Strategies to Evaluate Pharmacokinetic Models	10
IV. Evaluation of Dose-Dependent or Dose-Independent Pharmacokinetics	11
A. Are all drug transferences, metabolisms, and eliminations first-order processes?	11
B. Are dose-dependent pharmacokinetics solely due to saturable plasma protein binding?	14
V. Possible Assignments of Dose-Dependent Pharmacokinetics to Renal Processes	14
A. If dose-dependent pharmacokinetics exist and cannot be completely assigned to saturable plasma protein binding, can dose-dependent renal excretion be responsible?	14
B. If renal clearances vary with time, what are the criteria for concluding that there are dependencies on renal flow rates or urinary pH?	17